NCT01751165View on ClinicalTrials.gov

Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older

PHASE3CompletedINTERVENTIONAL
Enrollment

354

Participants

Timeline

Start Date

March 12, 2013

Primary Completion Date

May 22, 2014

Study Completion Date

April 8, 2015

Conditions
Herpes Zoster
Interventions
BIOLOGICAL

Herpes zoster vaccine GSK1437173A

2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.

Trial Locations (4)

15401

GSK Investigational Site, Uniontown

50106

GSK Investigational Site, Tartu

67207

GSK Investigational Site, Wichita

91978

GSK Investigational Site, Spring Valley

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01751165 - Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older | Biotech Hunter | Biotech Hunter